These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31991535)

  • 1. RUNX1 Dosage in Development and Cancer.
    Lie-A-Ling M; Mevel R; Patel R; Blyth K; Baena E; Kouskoff V; Lacaud G
    Mol Cells; 2020 Feb; 43(2):126-138. PubMed ID: 31991535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
    Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.
    Lam K; Zhang DE
    Front Biosci (Landmark Ed); 2012 Jan; 17(3):1120-39. PubMed ID: 22201794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.
    Yoshida T; Yamasaki K; Tadagaki K; Kuwahara Y; Matsumoto A; Sofovic AE; Kondo N; Sakai T; Okuda T
    Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34958111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runx1/AML1 in normal and abnormal hematopoiesis.
    Yamagata T; Maki K; Mitani K
    Int J Hematol; 2005 Jul; 82(1):1-8. PubMed ID: 16105753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis.
    Kalev-Zylinska ML; Horsfield JA; Flores MV; Postlethwait JH; Vitas MR; Baas AM; Crosier PS; Crosier KE
    Development; 2002 Apr; 129(8):2015-30. PubMed ID: 11934867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core binding factor genes and human leukemia.
    Hart SM; Foroni L
    Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis.
    Ichikawa M; Asai T; Chiba S; Kurokawa M; Ogawa S
    Cell Cycle; 2004 Jun; 3(6):722-4. PubMed ID: 15213471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
    Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
    Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium.
    Lie-A-Ling M; Marinopoulou E; Lilly AJ; Challinor M; Patel R; Lancrin C; Kouskoff V; Lacaud G
    Development; 2018 Mar; 145(5):. PubMed ID: 29530939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
    Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
    Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
    Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis.
    Liau WS; Ngoc PC; Sanda T
    Adv Exp Med Biol; 2017; 962():139-147. PubMed ID: 28299656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
    Ganly P; Walker LC; Morris CM
    Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
    Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
    Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.